TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: reductions of glucose weighted mean AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Estimated survival without negative events
Endpoint domain: Mortality/survival
Primary endpoint: Estimated survival without recementation or loss of pulp vitality
Endpoint domain: Mortality/survival
Primary endpoint: Mean ischial pressure during low pressure phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ischial pressure during high pressure phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long spike burst activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: colonic tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Absorption and transmittance in dental tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Definite stent thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Primary composite end point
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in number of hot flushes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of cyclic bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Esophageal perforation
Endpoint domain: Adverse events/effects
Primary endpoint: Fatalities
Endpoint domain: Mortality/survival
Primary endpoint: Seroprotection rates of diphtheria and tetanus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Solicited local adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Solicited systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute change in LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regional wall thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased flatulence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean lower leg growth rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ulcer healing and/or pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: major amputation or death
Endpoint domain: Mortality/survival
Primary endpoint: H1-receptor occupancy in cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional connectivity in reinforcement-related pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Growth outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute rejection incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: drainage reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: log WMFT time improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumour dose escalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lymph node dose escalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 60-day all-cause mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Neutrophils infiltrating the gastric mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: iNOS-expressing inflammatory cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proliferating cells in gastric epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urinary excretion values of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(t(last)) values of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) values of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: precision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficiency of the attentional system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: mRNA levels of chemokines and receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: spontaneous release of IL-8 and MIP-1alpha from PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of grades 3 and 4 thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: NLF correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of HSP70
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Size of salvaged myocardium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: STAT scores at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O2 cost
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preferred walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of treated patients who met the combined effectiveness measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression at 2 years
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety at 2 years
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: measures of disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Investigator Global Assessment score of 0/1 (cleared/minimal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 90% or greater improvement in PASI score from baseline (PASI 90)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ejection fraction among survivors after 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grade 3 or higher treatment‐related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: GAD severity ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of posttreatment GAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptoms remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: overall reaction time on a Stroop task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced somatic symptoms on the Brief Symptom Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: line-related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: removal of PICC line due to full enteral nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of glucose and insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oxidized LDL concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean amblyopic eye acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ulcer healing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Acceptability of outpatient hysteroscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hysterectomy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rate of outpatient hysteroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to hospital discharge (TTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nondevice related complication rates
Endpoint domain: Adverse events/effects
Primary endpoint: Hospital admission rate
Endpoint domain: Mortality/survival
Primary endpoint: Effect of fenofibric acid on CIMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Effect of treatment on LDL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of slitlike ventricles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Nasal congestion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FeNO decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uncontrolled symptoms reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of time-in-target glucose range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time spent below 4 mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient comfort during cataract surgery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain level during anesthesia administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of days before bleeding stopped
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days free of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Urinary incontinence rates at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: NHS costs in intervention group
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Development of freezing of gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: peak Borg (RPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PCA usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pain-at-its-least ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cesarean delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: risk of major morbidity
Endpoint domain: Mortality/survival
Primary endpoint: 1 yr mortality
Endpoint domain: Mortality/survival
Primary endpoint: sustained increase in EDSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: persistent pain at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction of wound length at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: aldosterone/renin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ACE concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: enhanced efficacy in fine lines, wrinkles and smoothness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response (SVR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed thrombotic CV events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hypertension-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: plasma concentrations of purines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: portal venous minus arterial purine plasma concentration differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative death
Endpoint domain: Mortality/survival
Primary endpoint: Complications after stoma construction
Endpoint domain: Adverse events/effects
Primary endpoint: Prolapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4(+) T-cell numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Tat antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Viral load rebound containment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in oral hygiene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in number of adolescents with healthy gums or mild inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in candy consumption
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: coefficients of variation of antithrombin effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: median new attachment loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hb drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hct drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Harris total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean platelet volume (MPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SCI-FAP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10MWT (fastest speed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAF recurrences at 1 year of follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMRadj
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: costs per quality‐adjusted life years gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Shorter survival associated with SMI loss
Endpoint domain: Mortality/survival
Primary endpoint: Genital self-image
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of women satisfying definition of postnatal depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving ACR20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving ACR50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving ACR70
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum alkaline phosphatase concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in urinary metabolites of lung carcinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin C(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: T(max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in FEV1 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Microalbuminuria excretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: MATRICS Consensus Cognitive Battery Working Memory composite change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Childbirth experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sick leave duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL-induced vascular toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ERK1/2 phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: soluble vascular cell adhesion molecule-1 production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum block height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAS-Cog (patient reported)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Conversion rate to a different procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of primary outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vitamin D insufficiency/deficiency improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean retromolar mineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood glucose response to gliclazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean area under the plasma concentration‐time curve for gliclazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean elimination half‐life of gliclazide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC0-12 h) of S-verapamil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC0-12 h) of R-verapamil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: N-terminal pro-B-type natriuretic peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Exercise capacity (V˙O2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical symptom scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in wheezing attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 52-week point prevalence abstinence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum amyloid A (SAA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improved functional outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhaled gas temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute humidity of inhaled gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean debris score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean calculus index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of children experiencing at least 1 AOM episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean number of AOM episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean duration of bilateral OME
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COPM scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall pixel classification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NL classification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: propofol and remifentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of microemboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: eGFR correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fatigue Severity Scale (FSS) scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Symptom Relief Index (SRI) scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: maximal isometric muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophageal varices eradication or reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bishop score of 3 or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of successful inductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to active labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes